Down-regulation of LATS kinases alters p53 to promote cell migration

Genes and Development

Volumn 29, Issue 22, 2015, Pages 2325-2330

  Furth, Noa ^a   Ben Moshe, Noa Bossel ^a   Pozniak, Yair ^b   Porat, Ziv ^a   Geiger, Tamar ^b   Domany, Eytan ^a   Aylon, Yael ^a   Oren, Moshe ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Cancer; Cell migration; COX 2; Homeostasis; NFKB2; TP53

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PHOSPHOTRANSFERASE; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE 2; PROTEIN P52; PROTEIN P53; TUMOR SUPPRESSOR LATS1; TUMOR SUPPRESSOR LATS2; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; CYCLOOXYGENASE 2; HIPPO PROTEIN, HUMAN; LATS1 PROTEIN, HUMAN; LATS2 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE; PTGS2 PROTEIN, HUMAN;

ARTICLE; BREAST CANCER; BREAST EPITHELIUM CELL; CELL MIGRATION; COMPARATIVE STUDY; CONTROLLED STUDY; DOWN REGULATION; ENZYME INDUCTION; EPITHELIUM CELL; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; MCF 7 CELL LINE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; CELL LINE; CELL MOTION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MUTATION; PHOSPHORYLATION;

CELL LINE; CELL MOVEMENT; CYCLOOXYGENASE 2; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MUTATION; NF-KAPPA B P52 SUBUNIT; PHOSPHORYLATION; PROTEIN CONFORMATION; PROTEIN-SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 84947976766     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.268185.115     Document Type: Article

References (41)

1. Adorno M, Cordenonsi M, Montagner M, Dupont S, Wong C, Hann B, Solari A, Bobisse S, Rondina MB, Guzzardo V, et al. 2009. A mutantp53/ Smad complex opposes p63 to empower TGFβ-induced metastasis. Cell 137: 87-98.
2. Aylon Y, Michael D, Shmueli A, Yabuta N, Nojima H, Oren M. 2006. A positive feedback loop between the p53 and Lats2 tumor suppressors prevents tetraploidization. Genes Dev 20: 2687-2700.
3. Aylon Y, Ofir-Rosenfeld Y, Yabuta N, Lapi E, Nojima H, Lu X, Oren M. 2010. The Lats2 tumor suppressor augments p53-mediated apoptosis by promoting the nuclear proapoptotic function of ASPP1. Genes Dev 24: 2420-2429.
4. Aylon Y, Sarver A, Tovy A, Ainbinder E, Oren M. 2014. Lats2 is critical for the pluripotency and proper differentiation of stem cells. Cell Death Differ 21: 624-633.
5. Bieging KT, Mello SS, Attardi LD. 2014. Unravelling mechanisms of p53- mediated tumour suppression. Nat Rev Cancer 14: 359-370.
6. Bode AM, Dong Z. 2004. Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer 4: 793-805.
7. Cordenonsi M, Montagner M, Adorno M, Zacchigna L, Martello G, Mamidi A, Soligo S, Dupont S, Piccolo S. 2007. Integration of TGF-β and Ras/ MAPK signaling through p53 phosphorylation. Science 315: 840-843.
8. Dannenberg AJ, Subbaramaiah K. 2003. Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell 4: 431-436.
9. Dupont S, Morsut L, Aragona M, Enzo E, Giulitti S, Cordenonsi M, Zanconato F, Le Digabel J, Forcato M, Bicciato S, et al. 2011. Role of YAP/ TAZ in mechanotransduction. Nature 474: 179-183.
10. Fogal V, Gostissa M, Sandy P, Zacchi P, Sternsdorf T, Jensen K, Pandolfi PP, Will H, Schneider C, Del Sal G. 2000. Regulation of p53 activity in nuclear bodies by a specific PML isoform. EMBO J 19: 6185-6195.
11. Gannon JV, Greaves R, Iggo R, Lane DP. 1990. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J 9: 1595-1602.
12. Gogna R, Madan E, Kuppusamy P, Pati U. 2012. Re-oxygenation causes hypoxic tumor regression through restoration of p53 wild-type conformation and post-translational modifications. Cell Death Dis 3: e286.
13. Iida S-i, Hirota T, Morisaki T, Marumoto T, Hara T, Kuninaka S, Honda S, Kosai K-i, Kawasuji M, Pallas DC, et al. 2004. Tumor suppressor WARTS ensures genomic integrity by regulating both mitotic progression andG1tetraploidy checkpoint function. Oncogene 23: 5266-5274.
14. Jänicke RU, Sohn D, Schulze-Osthoff K. 2008. The dark side of a tumor suppressor: anti-apoptotic p53. Cell Death Differ 15: 959-976.
15. Jiang Z, Li X, Hu J, ZhouW, Jiang Y, Li G, Lu D. 2006. Promoter hypermethylation- mediated down-regulation of LATS1 and LATS2 in human astrocytoma. Neurosci Res 56: 450-458.
16. Katayama H, Sasai K, Kawai H, Yuan Z-M, Bondaruk J, Suzuki F, Fujii S, Arlinghaus RB, Czerniak BA, Sen S. 2004. Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53. Nat Genet 36: 55-62.
17. MeekDW, Anderson CW. 2009. Posttranslational modification of p53: cooperative integrators of function. Cold Spring Harb Perspect Biol 1: a000950.
18. Milner J. 1995. Flexibility: the key to p53 function? Trends Biochem Sci 20: 49-51.
19. Moroishi T, Hansen CG, Guan K-L. 2015. The emerging roles of YAP and TAZ in cancer. Nat Rev Cancer 15: 73-79.
20. Mullany LK, Liu Z, King ER, Wong K-K, Richards JS. 2012. Wild-type tumor repressor protein 53 (Trp53) promotes ovarian cancer cell survival. Endocrinology 153: 1638-1648.
21. Muller PAJ, Vousden KH. 2013. p53 mutations in cancer. Nat Cell Biol 15: 2-8.
22. Nakade K, Zheng H, Ganguli G, Buchwalter G, Gross C, Wasylyk B. 2004. The tumor suppressor p53 inhibits Net, an effector of Ras/extracellular signal-regulated kinase signaling. Mol Cell Biol 24: 1132-1142.
23. Nakao S, Ogata Y, Shimizu-Sasaki E, Yamazaki M, Furuyama S, Sugiya H. 2000. Activation of NFκB is necessary for IL-1β-induced cyclooxygenase- 2 (COX-2) expression in human gingival fibroblasts. Mol Cell Biochem 209: 113-118.
24. Oren M, Aylon Y. 2013. The Hippo signaling pathway and cancer. Springer Science & Business Media, New York.
25. Rinon A, Molchadsky A, Nathan E, Yovel G, Rotter V, Sarig R, Tzahor E. 2011. p53 coordinates cranial neural crest cell growth and epithelial- mesenchymal transition/delamination processes. Development 138: 1827-1838.
26. Rivlin N, Katz S, Doody M, Sheffer M, Horesh S, Molchadsky A, Koifman G, Shetzer Y, Goldfinger N, Rotter V, et al. 2014. Rescue of embryonic stem cells from cellular transformation by proteomic stabilization of mutant p53 and conversion into WT conformation. Proc Natl Acad Sci 111: 7006-7011.
27. Scherz-Shouval R, Weidberg H, Gonen C, Wilder S, Elazar Z, Oren M. 2010. p53-dependent regulation of autophagy protein LC3 supports cancer cell survival under prolonged starvation. Proc Natl Acad Sci 107: 18511-18516.
28. Schoppy DW, Ruzankina Y, Brown EJ. 2010. Removing all obstacles: a critical role for p53 in promoting tissue renewal. Cell Cycle 9: 1313-1319.
29. Scian MJ, Stagliano KER, Anderson MAE, Hassan S, Bowman M, Miles MF, Deb SP, Deb S. 2005. Tumor-derived p53 mutants induce NF- κB2 gene expression. Mol Cell Biol 25: 10097-10110.
30. Singh B, Berry JA, Shoher A, Ramakrishnan V, Lucci A. 2005. COX-2 overexpression increases motility and invasion of breast cancer cells. Int J Oncol 26: 1393-1399.
31. Sorrentino G, Ruggeri N, Specchia V, Cordenonsi M, Mano M, Dupont S, Manfrin A, Ingallina E, Sommaggio R, Piazza S, et al. 2014. Metabolic control of YAP and TAZ by the mevalonate pathway. Nat Cell Biol 16: 357-366.
32. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al. 2005. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci 102: 15545-15550.
33. Takahashi Y, Miyoshi Y, Takahata C, Irahara N, Taguchi T, TamakiY, Noguchi S. 2005. Down-regulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers. Clin Cancer Res 11: 1380-1385.
34. Toji S, Yabuta N, Hosomi T, Nishihara S, Kobayashi T, Suzuki S, Tamai K, Nojima H. 2004. The centrosomal protein Lats2 is a phosphorylation target of Aurora-A kinase. Genes Cells 9: 383-397.
35. Trinidad AG, Muller PAJ, Cuellar J, Klejnot M, Nobis M, Valpuesta JM, Vousden KH. 2013. Interaction of p53 with the CCT complex promotes protein folding and wild-type p53 activity. Mol Cell 50: 805-817.
36. Vousden KH, Prives C. 2009. Blinded by the light: the growing complexity of p53. Cell 137: 413-431.
37. Yabuta N, Mukai S, Okada N, Aylon Y, Nojima H. 2011. The tumor suppressor Lats2 is pivotal in Aurora A and Aurora B signaling during mitosis. Cell Cycle 10: 2724-2736.
38. Yeudall WA, Vaughan CA, Miyazaki H, Ramamoorthy M, Choi M-Y, Chapman CG, Wang H, Black E, Bulysheva AA, Deb SP, et al. 2012. Gain-of-function mutant p53 upregulates CXC chemokines and enhances cell migration. Carcinogenesis 33: 442-451.
39. Zhang W, Deisseroth AB. 1994. Conformational change of p53 protein in growth factor-stimulated human myelogenous leukemia cells. Leuk Lymphoma 14: 251-255.
40. Zhang J, Smolen GA, Haber DA. 2008. Negative regulation of YAP by LATS1 underscores evolutionary conservation of the Drosophila Hippo pathway. Cancer Res 68: 2789-2794.
41. Zhao B, Li L, Lei Q, Guan K-L. 2010. The Hippo-YAP pathway in organ size control and tumorigenesis: an updated version. Genes Dev 24: 862-874.